GLPBio

3,4-Dihydroxybenzoic acid (Protocatechuic acid)

Catalog No.: GN10369Purity:>99.50%Synonyms: NSC 16631, PCA
3,4-Dihydroxybenzoic acid (Protocatechuic acid) is a natural polyphenolic compound found in many edible and medicinal plants.

Products are for research use only. Not for human use. We do not sell to patients.


3,4-Dihydroxybenzoic acid (Protocatechuic acid)
Cas No.: 99-50-3
10mM (in 1mL DMSO)In Stock
$35.00
1
200mgIn Stock
$28.00
1
1gIn Stock
$42.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

3,4-Dihydroxybenzoic acid (Protocatechuic acid) is a natural polyphenolic compound found in many edible and medicinal plants[1]. 3,4-Dihydroxybenzoic acid exhibits significant antioxidant activity[2], neuroprotective effects[3], and anticancer properties[4].

In vitro, treatment of human HepG2 hepatocellular carcinoma cells with 3,4-Dihydroxybenzoic acid (100μM) for 4 days induced cell death through a mechanism dependent on c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK)[5]. Treatment of human glioma cell lines U87 and U251 with 3,4-Dihydroxybenzoic acid (2.5–10μM) for 24–48 hours significantly inhibited cell proliferation, invasion, and migration, and induced pyroptosis via a mechanism dependent on the NLRP3/caspase-1/GSDMD signaling axis[6].

In vivo, dietary supplementation with 3,4-Dihydroxybenzoic acid (0.025–0.1%w/w) for 12 weeks in high-fat diet-fed C57BL/6J mice significantly ameliorated metabolic-associated fatty liver disease (MAFLD) by inhibiting the growth of Enterococcus faecalis in the gut and modulating insulin signaling pathways[7]. Intramuscular administration of 3,4-Dihydroxybenzoic acid (100mg/kg/day) for 9 days in an isoproterenol (80mg/kg/day)-induced heart failure model using C57BL/6 mice significantly improved cardiac function and attenuated cardiac hypertrophy and fibrosis[8].

References:
[1] Khan AK, Rashid R, Fatima N, et al. PHARMACOLOGICAL ACTIVITIES OF PROTOCATECHUIC ACID. Acta Pol Pharm. 2015 Jul-Aug;72(4):643-50.
[2] Zhang X, Luo J, Bharati L, Hua Z, et al. Protocatechuic acid suppresses ferroptosis to protect against hypoxic-ischemic encephalopathy by targeting the HIF-1α/VEGFA axis. Phytomedicine. 2025 Jul 25;143:156900.
[3] Krzysztoforska K, Mirowska-Guzel D, Widy-Tyszkiewicz E. Pharmacological effects of protocatechuic acid and its therapeutic potential in neurodegenerative diseases: Review on the basis of in vitro and in vivo studies in rodents and humans. Nutr Neurosci. 2019 Feb;22(2):72-82.
[4] Cadena-Iñiguez J, Santiago-Osorio E, Sánchez-Flores N, et al. The Cancer-Protective Potential of Protocatechuic Acid: A Narrative Review. Molecules. 2024 Mar 23;29(7):1439.
[5] Yip EC, Chan AS, Pang H, et al. Protocatechuic acid induces cell death in HepG2 hepatocellular carcinoma cells through a c-Jun N-terminal kinase-dependent mechanism. Cell Biol Toxicol. 2006 Jul;22(4):293-302.
[6] Zhang W, Cai Y, Zheng H. Protective Role of Protocatechuic Acid in Glioma: Modulation of Cell Growth, Migration, and Pyroptosis via NLRP3/Caspase-1/GSDMD Axis. Discov Med. 2025 Apr;37(195):659-668.
[7] Tan J, Hu R, Gong J, et al. Protection against Metabolic Associated Fatty Liver Disease by Protocatechuic Acid. Gut Microbes. 2023 Jan-Dec;15(1):2238959.
[8] Bai L, Han X, Kee HJ, et al. Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. J Cell Mol Med. 2023 Aug;27(16):2290-2307.

Protocol

Cell experiment [1]:

Cell lines

U87 and U251 cells (human glioma cell lines)

Preparation Method

Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C, 5% CO₂. Cells were treated with 3,4-Dihydroxybenzoic acid at concentrations of 2.5–10μM for 24–48 hours.

Reaction Conditions

2.5-10μM; 24–48 hours

Applications

3,4-Dihydroxybenzoic acid significantly suppressed cell viability, invasion, and migration in a dose-dependent manner. 3,4-Dihydroxybenzoic acid induced pyroptosis by upregulating NLRP3, caspase-1, and GSDMD expression, leading to increased GSDMD positivity.

Animal experiment [2]:

Animal models

C57BL/6NTac mice

Preparation Method

Mice were implanted with osmotic minipumps to continuously infuse Isoproterenol (80mg/kg) for 14 days to induce heart failure. 3,4-Dihydroxybenzoic acid (100mg/kg) was administered via daily intramuscular injections from day 6 to day 14 of isoproterenol infusion.

Dosage form

100mg/kg; i.m.

Applications

3,4-Dihydroxybenzoic acid significantly attenuated isoproterenol-induced cardiac hypertrophy, as evidenced by reduced heart-weight-to-body-weight ratio, decreased cardiomyocyte cross-sectional area, and downregulated expression of hypertrophy markers. 3,4-Dihydroxybenzoic acid improved cardiac function by increasing ejection fraction and fractional shortening, and reduced pulmonary edema.

References:
[1] Zhang W, Cai Y, Zheng H. Protective Role of Protocatechuic Acid in Glioma: Modulation of Cell Growth, Migration, and Pyroptosis via NLRP3/Caspase-1/GSDMD Axis. Discov Med. 2025 Apr;37(195):659-668.
[2] Bai L, Han X, Kee HJ, et al. Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. J Cell Mol Med. 2023 Aug;27(16):2290-2307.

Product Documents

Purity:>99.50%Appearance:A solid

Chemical Properties

CAS No.
99-50-3
Synonyms
NSC 16631, PCA
Chemical Name
3,4-dihydroxybenzoic acid
SMILES
C1=CC(=C(C=C1C(=O)O)O)O
Molecular Formula
C7H6O4
Molecular Weight
154.03
Solubility
≥ 4.9mg/mL in DMSO
Storage
-20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for 3,4-Dihydroxybenzoic acid (Protocatechuic acid)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%